Sector News

Pfizer to close Australia plant, whack 89 jobs

February 10, 2017
Life sciences

It’s a reversal of fortunes for a Pfizer plant in Australia. The U.S. drugmaker has decided to close the facility and lay off nearly 90 workers after announcing expansion plans for the site a year ago.

Pfizer has announced it will close the plant in Adelaide by the end of 2021 as it again consolidates its manufacturing, ABC News in Australia reported. The plant currently has 89 workers.

“This has been a difficult decision, and was based on a number of factors including the existing capacity within Pfizer’s global manufacturing network and the efficiency of consolidating manufacturing to fewer locations,” the company said in a statement, the news site reported.

The drugmaker announced in March last year it would invest about $15.7 million (AU$21 million) to expand the capacity at the Adelaide plant that makes pegfilgrastim, the active ingredient for Amgen’s cancer drug Neulasta.

It is the second Pfizer plant in Australia to be slated for closure in recent years. The drugmaker in 2015 closed a plant in Sydney, laying off about 140 workers.

By Eric Palmer

Source: Fierce Pharma

comments closed

Related News

January 22, 2023

Sun Pharma to buy Concert Pharmaceuticals for $576m

Life sciences

Sun Pharmaceutical Industries has signed a definitive agreement to buy all outstanding shares of Concert Pharmaceuticals in a deal valued at $576m. Under the deal, the company will buy all shares of Concert common stock through a tender offer for $8.00 per share in cash upfront payment.

January 22, 2023

Novo Nordisk diabetes pill wins FDA approval for first-line use

Life sciences

The Food and Drug Administration on Thursday approved Novo Nordisk’s diabetes pill Rybelsus as an initial treatment to lower blood sugar levels, a label expansion that will allow it to compete more directly with other oral drugs from Merck & Co. and Eli Lilly.

January 22, 2023

Bayer feeling more heat from activist investors, this time from Bluebell

Life sciences

Since making an ill-advised $63 billion buy of Monsanto in 2018, Bayer has faced heaps of pressure from investors that have called for the company to oust its leadership and to restructure. Now comes new pressure from a familiar source. Bluebell Capital Partners has bought an undisclosed stake in the company and is agitating for a breakup, sources told Reuters.

How can we help you?

We're easy to reach